Antimicrobial Drug Resistance

Clinical and Epidemiological Aspects, Volume 2

Inbunden, Engelska, 2017

Av Douglas L. Mayers, Jack D. Sobel, Marc Ouellette, Keith S. Kaye, Dror Marchaim

4 029 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives.

Produktinformation

Utgivningsdatum2017-07-07
Mått210 x 279 x 52 mm
Vikt2 345 g
FormatInbunden
SpråkEngelska
Antal sidor855
Upplaga2
FörlagSpringer International Publishing AG
ISBN9783319472645

Tillhör följande kategorier

Infektionssjukdomar och smittsamma sjukdomar inom Medicin
Patologi inom Medicin
Farmakologi inom Medicin
Sjukdomar och rubbningar inom Medicin

Douglas L. Mayers is an infectious diseases specialist and is currently Chief Medical Officer (CMO) at Cocrystal Pharma. Dr. Mayers received his M.D. from University of Pennsylvania and has over 20 years of medical and clinical development experience spanning all phases of global clinical research and development and commercialization. He has worked with the United States Army Medical Research Institute of Infectious Diseases to discover and develop drugs against the Ebola virus. He has also served as the Head of HIV Clinical Studies Program and Department of HIV Disease Prevention at the Walter Reed Army Institute of Research and Naval Medical Research Institute. Previously, he was the Chief Medical Officer and Executive Vice President at Idenix Pharmaceuticals, where he directed the Infectious Disease programs and led numerous regulatory filings globally, including successful advancement of several anti-HCV candidates to the clinical phase. Prior to Idenix, he was the International Head/Vice President of the Virology Therapeutic Area at Boehringer Ingelheim where he led Phase 1 through 4 clinical studies for HIV and hepatitis programs. In addition to his extensive expertise in the industry and in research, Dr. Mayers is well-known in the academic sphere and is the author of over 95 peer-reviewed publications and book chapters.

History of Drug-Resistant Microbes.- Evolutionary Biology of Drug Resistance.- Pharmacology of Drug Resistance.- Drug Development for Drug-Resistant Pathogens.- Genetic Mechanisms of Transfer of Drug Resistance.- Mutations as a Basis of Antimicrobial Resistance.- Altered Drug Targets.- Enzymatic Modification of Drugs.- Reduced Drug Penetration.- Active Efflux Mechanism.- Biofilms.- Beta-Lactamases.- Penicillin Binding Proteins.- Aminoglycosides.- Tetracyclines and ChloramphenicolQuinolones.- Plasmid Mediated Quinolone Resistance to Macrolides, Lincosamides, and Streptogramins.- Mechanisms of Resistance in Metronidazole.- Glycopeptide-resistance in eneterococci.- Daptomycin Resistance.- Oxazolidinones.- PolymyxinsSulfonamides and Trimethoprim.- Antimycobacterial Agents.- Amphotericin (Polyenes).- Azoles.- Flucytosine.- Echinocandins.- Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans.- Herpes Nucleoside Drugs.- Influenza Drugs.- HIV Nucleoside Drugs.- HIV Non-Nucleoside Drugs.- HIV Protease Inhibitors.- HIV Entry Inhibitors.- HIV Integrase Inhibitors.- Hepatitis B.- Hepatitis C.- Agents for anaerobic protozoa.- Antimalarial Agents.- Agents for Leishmania.- Agents for Trypanosomes.- Agents for Toxoplasma.- Agents for Cryptosporidium.- Agents against Nematodes.- Agents against Trematodes and Cestodes.- Agents against Ectoparasites.